On January 21, 2020 Novocure (NASDAQ: NVCR) reported that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical services basket for the treatment of patients with newly diagnosed glioblastoma (Press release, NovoCure, JAN 21, 2020, View Source [SID1234553377]). The medical services basket includes the entire range of services, medications and devices that the insured public in Israel is entitled to receive under the National Health Insurance Law.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are extremely pleased that the Ministry of Health has established national reimbursement for Optune in Israel," said Anat Bin, Novocure’s Country Manager of Israel. "Access to our therapy continues to grow throughout the world, demonstrating health insurers’ increasing recognition of Optune. We are committed to bringing Optune to as many patients who may benefit."